3 results on atopic dermatitis
To explore the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of LOU064 over a treatment period of 4 weeks in a cohort of subjects with atopic dermatitis.
Primary ObjectiveTo explore the pharmacodynamics effects of topically applied OMN ono Tape-stripped skin of healthy volunteerso Tape-stripped and IMQ-primed skin of healthy volunteerso Tape-stripped skin prior to IMQ applicationSecondary Objectives…
Primary Objectives1. To assess pruritus and rash after administration of Neublastin or placebo in healthy subjects and migraine patients (Parts A and B)2. To assess headache and other migraine-associated symptoms after administration of Neublastin…